No

Acetylcholinesterase Inhibitor; Ophthalmic Agent, Antiglaucoma; Ophthalmic Agent, Miotic

Treat primary open-angle glaucoma and conditions that obstruct aqueous outflow and to treat accommodative convergent strabismus

X

Active uveal inflammation, angle-closure (narrow-angle) glaucoma, known hypersensitivity to isoflurophate, pregnancy

May retard corneal healing; because of the tendency to produce more severe adverse effects, use the lowest dose possible; keep frequency of use to a minimum to avoid cyst formation; some products may contain sulfites

1% to 10%: Ocular: Stinging, burning eyes, myopia, visual blurring

<1%: Bradycardia, hypotension, flushing, nausea, vomiting, diarrhea, muscle weakness, retinal detachment, browache, miosis, twitching eyelids, watering eyes, dyspnea, diaphoresis

Symptoms of overdose include excessive salivation, urinary incontinence, dyspnea, diarrhea, profuse sweating

If systemic effects occur, administer parenteral atropine; for severe muscle weakness; pralidoxime may be used in addition to atropine

Increased toxicity: Succinylcholine, systemic anticholinesterases, carbamate or organic phosphate insecticides, may decrease cholinesterase levels

Protect from moisture, freezing, excessive heat

Cholinesterase inhibitor that causes contraction of the iris and ciliary muscles producing miosis, reduced intraocular pressure, and increased aqueous humor outflow

Peak IOP reduction: 24 hours; Duration: 1 week

Onset of miosis: Within 5-10 minutes; Duration: Up to 4 weeks

Adults: Ophthalmic:

Strabismus: Instill 0.25" strip to each eye every night for 2 weeks then reduce to 0.25" every other night to once weekly for 2 months

None reported

None reported

No information available to require special precautions

No effects or complications reported

Notify physician if abdominal cramps, diarrhea, or salivation occur

Keep tube tightly closed to prevent absorption of moisture and loss of potency

Ointment, ophthalmic: 0.025% in polyethylene mineral oil gel (3.5 g)